Sector News

New Stada CEO demotes predecessor's son, sacks advisors

June 27, 2016
Life sciences

The new chief executive of Germany’s Stada, who took over after his predecessor Harmut Retzlaff left for health reasons, has stripped Retzlaff’s son Steffen of some responsibilities and has fired the former CEO’s external advisors, taking a firmer grip of the maker of generic drugs and consumer care products.

Stada earlier this month said its long-time chief executive Harmut Retzlaff would temporarily leave office for health reasons and that fellow executive board member Matthias Wiedenfels would take over as CEO.

Steffen Retzlaff will no longer be in charge of Stada subsidiaries Hemopharm GmbH and Stadavita GmbH and will focus on his responsibility for the regions Asia and Pacific, Middle East and North Africa, Wiedenfels told staff in a letter dated June 20, which was obtained by Reuters.

A company spokesman confirmed the contents of the letter.

External advisors which have been acting as “Senior Advisors to the CEO” have been relieved of their duties, Wiedenfels told staff in the letter.

By Alexander Huebner

Source: Reuters

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.